{"id":7559,"date":"2026-05-19T01:01:00","date_gmt":"2026-05-18T23:01:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=997bd15365d5ab36b48f43b04db10ea9"},"modified":"2026-05-19T01:01:00","modified_gmt":"2026-05-18T23:01:00","slug":"stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=7559","title":{"rendered":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"},"content":{"rendered":"

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.<\/a> (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p><\/a><\/a>

\nThe stock options that were granted have an exercise price of $30.08 per share, which is equal to the closing price of Stoke\u2019s common stock on May 15, 2026. Each option will vest over a 4-year period, with 1\/4th<\/sup> of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1\/48th<\/sup> of the shares underlying each employee\u2019s option over the following 36 months, subject to the employee\u2019s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.<\/p>

\nAbout Stoke Therapeutics\n<\/b>Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine. Using Stoke\u2019s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke\u2019s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke\u2019s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke\u2019s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https:\/\/www.stoketherapeutics.com\/<\/a>.<\/p> Contacts<\/b>

\nStoke Media & Investor Contacts:<\/b>Susan Willson\nVice President, Corporate Communications\nswillson@stoketherapeutics.com<\/a>415-509-8202\n\nDoug Snow\nDirector, Communications & Investor Relations\nIR@stoketherapeutics.com<\/a>508-642-6485<\/p>","protected":false},"excerpt":{"rendered":"

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7559","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7559"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7559\/revisions"}],"predecessor-version":[{"id":7560,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7559\/revisions\/7560"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}